Follow us on Twitter
twitter icon@FreshPatents


Syndrome X patents

      

This page is updated frequently with new Syndrome X-related patent applications.




Insulin sensitisers and methods of treatment
The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease.
Naia Metabolic, Inc.


Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.


Treatment of metabolic disorders in canine animals
The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or syndrome x (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.. .
Boehringer Ingelheim Vetmedica Gmbh


Spirocyclic compounds containing spiro[indolyl-3,1'-pyrrolo[3,4-c]pyrrole] core and sulphur-containing amino acid residues
The present invention relates to spirocyclic compounds on the basis of 2-oxindole derivatives containing a spiro[indolyl-3,1′-pyrrolo[3,4-c]-pyrrole] core and biogenic sulphur-containing amino acid residues, which display a glucocorticoid-mimicking action by influencing 11β-hsd1 enzyme cortisone->cortisol conversion, or by inhibiting grs- or gitr- or mineralocorticoid receptors, or other targets, but do not interfere with steroidal haemostasis in hpa; and compositions containing same and their use for therapy as part of undifferentiated stroke therapy (in the absence of final verification of the stroke subtype) at various stages of acute ischemic stroke (ais), during the period of recovery from stroke and craniocerebral trauma, in patients with chronic cerebrovascular pathology (against a background of diabetes), in combinational therapy for alzheimer's disease and encephalopathy of various origin (discirculatory, alcoholic, infectious-toxic), and diabetes, combinational therapy for retinal degenerative eye diseases, as part of combinational therapy for metabolic syndrome (obesity, in patients suffering from cushing's syndrome, reaven metabolic syndrome (also known as syndrome x or insulin resistance syndrome) and other diseases where gcs hormones play a key role.. .

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof
The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as syndrome x and/or polycystic ovary disease..
Metabasis Therapeutics, Inc.


Engineered polypeptides having enhanced duration of action and reduced immunogenicity
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Pharmaceutical compounds
The present invention provides hydroxychloroquine or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of systolic heart failure, sincus tachycardia, cardiac syndrome x and/or essential hypertension.. .
Isis Innovation Ltd


Engineered polypeptides having enhanced duration of action
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
Aegerion Pharmaceuticals, Inc.


Methods and formulations for modulating lyn kinase activity and treating related disorders
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..
Melior Pharmaceuticals I, Inc.


Combination therapy for the treatment of diabetes
The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein..
Janssen Pharmaceutica N.v.


Highly soluble leptins

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii).
Aegerion Pharmaceuticals, Inc.

Antidiabetic enolic glucoside of phenylpyruvic acid

There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. For lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome x.
Zadec Aps

Novel 3-(4(benzyloxy)phenyl)hex-4-inoic acid derivative, preparing same and pharmaceutical composition for preventing and treating metabolic disease including same as effective ingredient

The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating gpr40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs.
Hyundai Pharm Co., Ltd

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., syndrome x), thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.

Formulation for co-therapy treatment of diabetes

The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x.. .
Janssen Pharmaceutica Nv

Compositions containing berberine and pantethine and methods for treatment of lipid metabolism disorders

The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as hypercholesterolemia, hyperlipidemia, elevated triglycerides, syndrome x (metabolic syndrome), hyperglycemia, diabetes, cardiovascular disease and the like as well as disorders of lipid metabolism with failed response to standard therapies (for example statins) or any other disease or condition associated with lipids and lipid metabolism, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate combinations of berberine and pantethine, alone or with one or more of chromium polynicotinate or chromium picolinate, biotin, curcumin and/or bioperin..

Method of weight reduction

The present disclosure relates generally to the use of methazolamide in therapy. The disclosure particularly relates to regulation of glucose homeostasis and reduction of body mass in patients suffering from or susceptible to diseases and associated conditions, in which undesirably high blood glucose levels are involved or implicated, such as diabetes, syndrome x, hyper-glycaemia, vascular disease and kidney disease.
Vera Pharmaceuticals Ltd

Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof

The invention pertains to the use of fused bicyclo heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol o-acyltransferase 1 (dgat-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as syndrome x and/or polycystic ovary disease..
Metabasis Therapeutics, Inc.

Treatment of metabolic disorders in feline animals

The present invention relates to one or more sglt2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or syndrome x (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.. .
Boehringer Ingelheim Vetmedica Gmbh

Compositions and methods for the treatment of sleep apnea

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies..

Combination therapy for the treatment of diabetes

The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein..
Janssen Pharmaceutica N.v.

Organic compounds

Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula i can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome x, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.

Indazole compounds useful as ketohexokinase inhibitors

The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (khk) inhibitors, useful for treating or ameliorating a khk mediated metabolic disorders and/or diseases such as obesity, type ii diabetes mellitus and metabolic syndrome x..

Combination therapy for effecting weight loss and treating obesity

The combination methods of the present invention also are effective against symptoms associated with syndrome x. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies..

Method for treating disease or condition susceptible to amelioration by ampk activators and compounds of formula which are useful to activate amp-activated protein kinase (ampk)

The present invention relates to a method for treating disease or condition susceptible to amelioration by ampk activators and compounds of formula which are useful to activate amp-activated protein kinase (ampk) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome x, metabolic syndrome and obesity.. .

Formulation for co-therapy treatment of diabetes

The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as type 2 diabetes mellitus and syndrome x.. .

Engineered poypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.

Ketone compounds and compositions for cholesterol management and related uses

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing alzheimer's disease, syndrome x, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence.

Methods and formulations for modulating lyn kinase activity and treating related disorders

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder including cardiovascular disease, dyslipidemia, dyslipoproteinemia, a disorder of glucose metabolism, metabolic syndrome (i.e., syndrome x), a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, type ii diabetes, obesity, pancreatitis, hypertension, renal disease, inflammation, or impotence..

Genes frequently altered in pancreatic neuroendocrine tumors

Pancreatic neuroendocrine tumors (pannets) are a rare but clinically important form of pancreatic neoplasia. To explore the genetic basis of pannets, we determined the exomic sequences of ten non-familial pannets and then screened the most commonly mutated genes in 58 additional pannets.

Compositions, methods and kits relating to resistin

The invention relates to novel nucleic acids encoding a mammalian resistin gene, and proteins encoded thereby, whose expression is suppressed by the antidiabetic compounds thiazolidinediones. The invention further relates to methods of treating and detecting type 2 diabetes and syndrome x comprising modulating or detecting resistin expression and/or production and activity of resistin polypeptide..

Insulin sensitisers and methods of treatment

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease.



Syndrome X topics:
  • Syndrome X
  • Metabolic Syndrome
  • Dyslipidemia
  • C Syndrome
  • Hypertension
  • Insulin Resistance
  • Inflammation
  • Nephropathy
  • Hyperlipidemia
  • Vascular Disease
  • Cardiovascular
  • Tic Disorder
  • Lipoprotein
  • Cardiovascular Disease
  • Dysfunction


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Syndrome X for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Syndrome X with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.253

    file did exist - 1895

    0 - 1 - 40